Peter Whish-Wilson (Tasmania, Australian Greens) Share this | Hansard source

My question is to Senator Payne, Minister representing the Minister for Trade. This week five health experts from the Centre for Health Equity Training Research and Evaluation at the University of New South Wales published a report on the impact of the Trans-Pacific Partnership Agreement on medicine prices. Their expert analysis of a leaked chapter of the Trans-Pacific Partnership Agreement says the TPP will lead to a rise in medicine prices in Australia. Minister, will you specifically rule out that Australia is prepared, as part of the TPP negotiations, to extend the time taken for medicines to become generics, or that cutting edge medicines like biologics will have their data and market exclusivity period extended?